A5071781807- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Brain Metastases and Treatment
- BRCA gene mutations in cancer
- Cancer Immunotherapy and Biomarkers
- Chemotherapy-induced cardiotoxicity and mitigation
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Ethics in Clinical Research
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Ubiquitin and proteasome pathways
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer survivorship and care
- Treatment of Major Depression
- Multiple Myeloma Research and Treatments
Nanjing Medical University
2023-2024
Hubei University of Medicine
2024
Central South University
2024
Inner Mongolia People's Hospital
2024
Hebei Medical University
2024
Fourth Hospital of Hebei Medical University
2024
Henan Cancer Hospital
2024
Zhengzhou University
2024
Guangxi Medical University
2024
Hebei University
2023
No single standard treatment exists for patients with small, node-negative, human epidermal growth factor receptor type 2 (HER2)-positive breast cancers, because most of these have been ineligible the pivotal trials adjuvant trastuzumab.We performed an uncontrolled, single-group, multicenter, investigator-initiated study paclitaxel and trastuzumab in 406 tumors measuring up to 3 cm greatest dimension. Patients received weekly 12 weeks, followed by 9 months monotherapy. The primary end point...
The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)-positive breast cancer. primary analysis the demonstrated a 3-year disease-free survival (DFS) 98.7%. In this planned secondary analysis, we report longer-term outcomes exploratory results characterize biology HER2-positive tumors genetic factors that may predispose paclitaxel-induced peripheral neuropathy (TIPN).In phase II study, cancer 3 cm...
Purpose Cell-free DNA (cfDNA) offers the potential for minimally invasive genome-wide profiling of tumor alterations without biopsy and may be associated with patient prognosis. Triple-negative breast cancer (TNBC) is characterized by few mutations but extensive somatic copy number (SCNAs), yet little known regarding SCNAs in metastatic TNBC. We sought to evaluate TNBC exclusively via cfDNA determine if fraction overall survival Patients Methods In this retrospective cohort study, we...
Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated safety efficacy of ruxolitinib patients with metastatic This was non-randomized phase II study enrolling refractory, triple-negative The primary endpoint objective response by RECIST 1.1. designed to enroll whose archival tumor tissue pSTAT3-positive (T-score >5) central immunohistochemistry. pSTAT3...
Currently, no targeted therapies are available for metastatic triplenegative breast cancer (mTNBC). We evaluated the safety, efficacy, and biomarkers of response to cabozantinib, a multikinase inhibitor, in patients with mTNBC. conducted single arm phase II biomarker study that enrolled measurable Patients received cabozantinib (60 mg daily) on 3-week cycle were restaged after 6 weeks then every 9 weeks. The primary endpoint was objective rate. Predefined secondary endpoints included...
Abstract Background Treatment options for triple-negative breast cancer remain limited. Activation of the PI3K pathway via loss PTEN and/or INPP4B is common. Buparlisib an orally bioavailable, pan-class I inhibitor. We evaluated safety and efficacy buparlisib in patients with metastatic cancer. Methods This was a single-arm phase 2 study enrolling Patients were treated at starting dose 100 mg daily. The primary endpoint clinical benefit, defined as confirmed complete response (CR), partial...
Background. It is hypothesized that free radical damage contributes to aging. Age-related decline in activity of the antioxidant enzyme glutathione peroxidase (GPx) may contribute increased radicals. We GPx decreases with age a population older women disability.
Trastuzumab is a life-saving therapy but associated with symptomatic and asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic effects of nonanthracycline trastuzumab-based treatment for patients early-stage human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)-positive breast cancer.To determine safety paclitaxel trastuzumab utility LVEF monitoring in node-negative, ERBB2-positive cancer.In this secondary analysis an uncontrolled,...
Lapatinib plus trastuzumab improves outcomes relative to lapatinib alone in heavily pretreated, human epidermal growth factor receptor 2-positive metastatic breast cancer (MBC). We tested the combination earlier-line setting and explored predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]FDG-PET) for clinical outcomes.Two cohorts were enrolled (cohort 1: no prior MBC ≥ 1 year from adjuvant trastuzumab, if given; cohort 2: one two lines chemotherapy including...
511 Background: Retrospective data suggest that patients (pts) with small HER2+ cancers have more than just minimal risk of disease recurrence. The APT trial was designed to address treatment for such pts. We previously reported 3-yr disease-free survival (DFS) and here we provide an updated analysis 7-yr DFS. Methods: is a single arm multicenter, phase II study TH. Pts BC (IHC 3+ and/or FISH ratio > 2.0) negative nodes (a axillary lymph node micrometastasis allowed) tumor size < 3 cm...
MET expression and activation appear to be important for initiation progression of triple-negative breast cancer. Tivantinib (ARQ 197) is an orally administered agent that targets MET, although recent preclinical data suggests the may have mechanisms action are independent signaling. We conducted a phase 2 study tivantinib monotherapy in patients with metastatic cancer.Patients cancer who had received 1 3 prior lines chemotherapy setting were enrolled into this two-stage, single arm study....
The aim of CATS (Cardiotoxicity Adjuvant Trastuzumab Study) was to prospectively assess clinical, biochemical, and genomic predictors trastuzumab-related cardiotoxicity (TRC). Cardiac dysfunction is a common adverse effect trastuzumab. Studies identify predictive biomarkers for TRC have enrolled heterogeneous populations yielded mixed results. A total 222 patients with early-stage human epidermal growth factor receptor 2–positive breast cancer scheduled receive adjuvant anthracyclines...
This study aims to explore differences between health misinformation and true information by comparing word usage, sentiments, online popularity pro- anti-vaccine headlines (PVHs AVHs). Text mining sentiment analysis showed that AVHs were more likely use negative words trust-related words. PVHs related positive sentiments. Anti-vaccine messages (AVMs) popular than pro-vaccine (PVMs). AVMs' was not its emotion usage. Among PVMs, those with be shared, commented on, reacted online. Wordclouds...
In contrast to recurrence after initial diagnosis of stage I-III breast cancer [recurrent metastatic (rMBC)], de novo (dnMBC) represents a unique setting elucidate drivers in the absence treatment selection. We present genomic landscape dnMBC and association with overall survival (OS).Targeted DNA sequencing (OncoPanel) was prospectively performed on either primary or tumors from 926 patients (212 714 rMBC). Single-nucleotide variants, copy-number variations, tumor mutational burden (TMB)...
Abstract Background: Four large randomized phase III trials have reported significant improvements in disease-free (DFS) and overall survival for H administered with adjuvant polychemotherapy HER2-positive high-risk BC. With the success of HER2-targeting, limiting chemotherapy is both reasonable feasible, particularly smaller, node-negative tumors. However data are limited. Methods: APT a single arm three-stage, multicenter, II study TH. Patients (pts) BC (IHC 3 + and/or FISH amplified at...
Previous data suggest that the immune microenvironment plays a critical role in human epidermal growth factor receptor 2 (HER2) -positive breast cancer; however, there is little known about profiles of small HER2-positive tumors. In this study, we aimed to characterize cancers included Adjuvant paclitaxel and trastuzumab for node-negative, cancer (APT) trial correlate markers with pathological molecular tumor characteristics.